MA49726B1 - Formulation d'anticorps anti-cgrp - Google Patents
Formulation d'anticorps anti-cgrpInfo
- Publication number
- MA49726B1 MA49726B1 MA49726A MA49726A MA49726B1 MA 49726 B1 MA49726 B1 MA 49726B1 MA 49726 A MA49726 A MA 49726A MA 49726 A MA49726 A MA 49726A MA 49726 B1 MA49726 B1 MA 49726B1
- Authority
- MA
- Morocco
- Prior art keywords
- antibody formulation
- cgrp antibody
- headaches
- episodic
- chronic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cette invention concerne des formulations pharmaceutiques d'anticorps anti-CGRP, et leurs procédés d'utilisation, lesdites formulations étant utiles dans le traitement des migraines, des maux de tête épisodiques, des maux de tête chroniques, des céphalées en grappe chroniques, et des céphalées en grappe épisodiques.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562180905P | 2015-06-17 | 2015-06-17 | |
| EP16729483.4A EP3310809B1 (fr) | 2015-06-17 | 2016-06-08 | Formulation d'anticorps anti-cgrp |
| PCT/US2016/036407 WO2016205037A1 (fr) | 2015-06-17 | 2016-06-08 | Formulation d'anticorps anti-cgrp |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA49726A MA49726A (fr) | 2020-06-10 |
| MA49726B1 true MA49726B1 (fr) | 2025-02-28 |
Family
ID=56131672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA49726A MA49726B1 (fr) | 2015-06-17 | 2016-06-08 | Formulation d'anticorps anti-cgrp |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US11498959B2 (fr) |
| EP (2) | EP4470557A3 (fr) |
| JP (1) | JP6438599B2 (fr) |
| KR (1) | KR102000867B1 (fr) |
| CN (4) | CN114948847A (fr) |
| AR (2) | AR104847A1 (fr) |
| AU (1) | AU2016280555B2 (fr) |
| BR (1) | BR112017023374A2 (fr) |
| CA (1) | CA2984185A1 (fr) |
| DK (1) | DK3310809T3 (fr) |
| EA (1) | EA037580B1 (fr) |
| ES (1) | ES3000607T3 (fr) |
| FI (1) | FI3310809T3 (fr) |
| HR (1) | HRP20241660T1 (fr) |
| HU (1) | HUE069368T2 (fr) |
| IL (2) | IL292562A (fr) |
| JO (1) | JO3772B1 (fr) |
| LT (1) | LT3310809T (fr) |
| MA (1) | MA49726B1 (fr) |
| MD (1) | MD3310809T2 (fr) |
| MX (1) | MX395147B (fr) |
| MY (1) | MY184266A (fr) |
| NZ (1) | NZ737046A (fr) |
| PL (1) | PL3310809T3 (fr) |
| PT (1) | PT3310809T (fr) |
| RS (1) | RS66243B1 (fr) |
| SI (1) | SI3310809T1 (fr) |
| TW (1) | TWI725973B (fr) |
| UA (1) | UA120881C2 (fr) |
| WO (1) | WO2016205037A1 (fr) |
| ZA (1) | ZA201707324B (fr) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
| US12257272B2 (en) | 2015-12-24 | 2025-03-25 | Seed Health, Inc. | Method and system for reducing the likelihood of developing depression in an individual |
| US12279989B2 (en) | 2011-02-04 | 2025-04-22 | Seed Health, Inc. | Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity |
| US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
| US12533312B2 (en) | 2011-02-04 | 2026-01-27 | Seed Health, Inc. | Method and system for preventing sore throat in humans |
| US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
| US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
| US12329783B2 (en) | 2013-12-20 | 2025-06-17 | Seed Health, Inc. | Method and system to improve the health of a person's skin microbiome |
| US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
| US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
| US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
| US12246043B2 (en) | 2013-12-20 | 2025-03-11 | Seed Health, Inc. | Topical application to treat acne vulgaris |
| US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
| US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
| US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
| US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| MX378344B (es) | 2014-03-21 | 2025-03-10 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| EP3515488A1 (fr) * | 2016-09-23 | 2019-07-31 | Teva Pharmaceuticals International GmbH | Traitement de l'algie vasculaire de la face |
| SMT202600087T1 (it) | 2016-09-23 | 2026-03-09 | Teva Pharmaceuticals Int Gmbh | Trattamento dell’emicrania refrattaria |
| JP7195262B2 (ja) | 2017-03-02 | 2022-12-23 | ベス イスラエル デアコネス メディカル センター インコーポレイティッド | カルシトニン遺伝子関連ペプチドを指向する抗体に応答性の頭痛患者の選択方法 |
| TWI754772B (zh) * | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
| SG11202009629YA (en) * | 2018-04-02 | 2020-10-29 | Amgen Inc | Erenumab compositions and uses thereof |
| WO2019231800A1 (fr) * | 2018-05-31 | 2019-12-05 | Eli Lilly And Company | Anticorps anti-cgrp pour le traitement des migraines liées aux menstruations |
| JP7465260B2 (ja) * | 2018-09-20 | 2024-04-10 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー | 充填済シリンジおよび自動注射器 |
| CR20210373A (es) | 2019-01-08 | 2021-08-19 | H Lundbeck As | Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp |
| GEAP202515803A (en) | 2019-05-02 | 2025-06-10 | H Lundbeck As | Treatment of headache using anti-cgrp antibodies |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| JP2024509165A (ja) | 2021-03-02 | 2024-02-29 | シージーアールピー ダイアグノスティクス ゲーエムベーハー | 片頭痛の治療及び/又は発生の低減 |
| WO2023026205A1 (fr) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Traitement préventif de la migraine |
| WO2026098547A1 (fr) * | 2024-11-08 | 2026-05-15 | 湖北生物医药产业技术研究院有限公司 | Anticorps ciblant cgrp et son utilisation |
| WO2026149405A1 (fr) * | 2025-01-10 | 2026-07-16 | 齐鲁制药有限公司 | Composition pharmaceutique comprenant un anticorps anti-cgrp humain |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE198277T1 (de) | 1992-10-02 | 2001-01-15 | Genetics Inst | Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator |
| TW518219B (en) | 1996-04-26 | 2003-01-21 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
| US20030138417A1 (en) * | 2001-11-08 | 2003-07-24 | Kaisheva Elizabet A. | Stable liquid pharmaceutical formulation of IgG antibodies |
| CN103040732B (zh) | 2003-02-10 | 2015-04-01 | 伊兰药品公司 | 免疫球蛋白制剂及其制备方法 |
| PA8661401A1 (es) * | 2005-01-28 | 2006-09-08 | Wyeth Corp | Formulaciones del liquido polipeptido estabilizado |
| GT200600031A (es) | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| EP1865986B1 (fr) | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Compositions d'anticorps anti-ctla-4 |
| KR20080074120A (ko) * | 2005-10-13 | 2008-08-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물 |
| US9168286B2 (en) * | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| SI3045182T1 (en) | 2005-11-14 | 2018-08-31 | Teva Pharmaceuticals International Gmbh | An antibody to a peptide-associated peptide antagonist to calcitonin for treating a headache in aggregates |
| WO2007123765A2 (fr) | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha |
| CN101553504A (zh) * | 2006-12-11 | 2009-10-07 | 豪夫迈·罗氏有限公司 | Aβ抗体胃肠外制剂 |
| JP5419709B2 (ja) * | 2007-01-09 | 2014-02-19 | ワイス・エルエルシー | 抗il−13抗体製剤およびその使用 |
| CA2681743A1 (fr) * | 2007-03-22 | 2008-09-25 | Imclone Llc | Formulations d'anticorps stables |
| KR101540823B1 (ko) | 2007-03-30 | 2015-07-30 | 메디뮨 엘엘씨 | 항체 제제 |
| WO2008131298A2 (fr) * | 2007-04-18 | 2008-10-30 | Elan Pharma International Limited | Prévention et traitement d'angiopathie amyloïde cérébrale |
| SI2331090T1 (en) * | 2008-09-19 | 2018-04-30 | Pfizer Inc. | Stable liquid antibody formulation |
| RU2481824C2 (ru) | 2008-10-29 | 2013-05-20 | Аблинкс Н.В | Препараты однодоменных антигенсвязывающих молекул |
| WO2010056804A1 (fr) * | 2008-11-12 | 2010-05-20 | Medimmune, Llc | Formulation d’anticorps |
| MX2011005672A (es) * | 2008-11-28 | 2011-06-20 | Abbott Lab | Composiciones de anticuerpo estables y metodos para estabilizar a las mismas. |
| EP2196476A1 (fr) | 2008-12-10 | 2010-06-16 | Novartis Ag | Formulation d'anticorps |
| CN102413839A (zh) * | 2009-03-06 | 2012-04-11 | 医学免疫有限责任公司 | 人源化抗cd19抗体制剂 |
| JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| JO3330B1 (ar) * | 2010-06-10 | 2019-03-13 | Lilly Co Eli | الأجسام المضادة cgrp |
| CA2808975C (fr) * | 2010-08-23 | 2018-10-30 | Wyeth Llc | Formulations stables des antigenes rlp2086 de neisseria meningitidis |
| WO2012135408A1 (fr) * | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | Formulations stables d'anticorps dirigés contre le récepteur humain pd-1 de la mort programmée et traitements associés |
| PT3495392T (pt) * | 2011-05-20 | 2021-09-22 | H Lundbeck As | Composições anti-cgrp e a sua utilização |
| AU2012328921B2 (en) | 2011-10-24 | 2017-05-11 | Abbvie Inc. | Immunobinders directed against TNF |
| WO2014031718A1 (fr) * | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Formulations stables d'anticorps contre la tslp |
| WO2014114651A1 (fr) * | 2013-01-24 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Protéines de liaison à l'antigène tnf-alpha |
| MX378344B (es) * | 2014-03-21 | 2025-03-10 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos. |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| JP6592600B2 (ja) * | 2015-10-30 | 2019-10-16 | イーライ リリー アンド カンパニー | 抗cgrp/抗il−23二重特異性抗体及びその使用 |
-
2016
- 2016-06-01 AR ARP160101603A patent/AR104847A1/es not_active Application Discontinuation
- 2016-06-02 TW TW105117447A patent/TWI725973B/zh active
- 2016-06-05 JO JOP/2016/0111A patent/JO3772B1/ar active
- 2016-06-08 CN CN202210229605.2A patent/CN114948847A/zh active Pending
- 2016-06-08 LT LTEPPCT/US2016/036407T patent/LT3310809T/lt unknown
- 2016-06-08 DK DK16729483.4T patent/DK3310809T3/da active
- 2016-06-08 HU HUE16729483A patent/HUE069368T2/hu unknown
- 2016-06-08 MY MYPI2017704814A patent/MY184266A/en unknown
- 2016-06-08 SI SI201631867T patent/SI3310809T1/sl unknown
- 2016-06-08 JP JP2017564734A patent/JP6438599B2/ja active Active
- 2016-06-08 IL IL292562A patent/IL292562A/en unknown
- 2016-06-08 KR KR1020177035870A patent/KR102000867B1/ko active Active
- 2016-06-08 CA CA2984185A patent/CA2984185A1/fr active Pending
- 2016-06-08 FI FIEP16729483.4T patent/FI3310809T3/fi active
- 2016-06-08 UA UAA201712093A patent/UA120881C2/uk unknown
- 2016-06-08 PT PT167294834T patent/PT3310809T/pt unknown
- 2016-06-08 ES ES16729483T patent/ES3000607T3/es active Active
- 2016-06-08 EP EP24201727.5A patent/EP4470557A3/fr active Pending
- 2016-06-08 MD MDE20180401T patent/MD3310809T2/ro unknown
- 2016-06-08 MX MX2017016199A patent/MX395147B/es unknown
- 2016-06-08 AU AU2016280555A patent/AU2016280555B2/en active Active
- 2016-06-08 BR BR112017023374-6A patent/BR112017023374A2/pt not_active Application Discontinuation
- 2016-06-08 WO PCT/US2016/036407 patent/WO2016205037A1/fr not_active Ceased
- 2016-06-08 RS RS20241326A patent/RS66243B1/sr unknown
- 2016-06-08 CN CN201680034297.0A patent/CN107787229A/zh active Pending
- 2016-06-08 MA MA49726A patent/MA49726B1/fr unknown
- 2016-06-08 EA EA201792359A patent/EA037580B1/ru not_active IP Right Cessation
- 2016-06-08 PL PL16729483.4T patent/PL3310809T3/pl unknown
- 2016-06-08 US US15/578,263 patent/US11498959B2/en active Active
- 2016-06-08 NZ NZ73704616A patent/NZ737046A/en unknown
- 2016-06-08 EP EP16729483.4A patent/EP3310809B1/fr active Active
- 2016-06-08 HR HRP20241660TT patent/HRP20241660T1/hr unknown
- 2016-06-08 CN CN202410340972.9A patent/CN118356393A/zh active Pending
- 2016-06-08 CN CN202610572399.3A patent/CN122479108A/zh active Pending
-
2017
- 2017-10-27 ZA ZA2017/07324A patent/ZA201707324B/en unknown
- 2017-11-05 IL IL255443A patent/IL255443B/en unknown
-
2021
- 2021-12-17 US US17/554,713 patent/US20220112277A1/en active Pending
-
2022
- 2022-08-08 US US17/883,072 patent/US20230159628A1/en active Pending
-
2024
- 2024-08-02 AR ARP240102059A patent/AR133453A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX395147B (es) | Formulación de anticuerpo anti-cgrp. | |
| PH12020500240A1 (en) | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies | |
| SA519401522B1 (ar) | Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات | |
| MA53356B1 (fr) | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations | |
| MA37538B1 (fr) | Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation | |
| MA42447A (fr) | Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation | |
| MA40513A (fr) | Conjugués médicament-anticorps anti-cdh6 | |
| EP3645742A4 (fr) | Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation | |
| EP3386536A4 (fr) | Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation | |
| MA46770A (fr) | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation | |
| MA40682B1 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
| EA201792616A1 (ru) | Средства, пути применения и способы лечения синуклеопатии | |
| EA201891983A1 (ru) | Комбинированная терапия антителами к cd73 | |
| MX381232B (es) | Formulación de anticuerpos. | |
| MA40576A (fr) | Anticorps et immunoconjugués anti-her2 | |
| EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
| EA201890278A1 (ru) | Антитела к pd-l1 | |
| EA201690618A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| MA38554A3 (fr) | Anticorps bispécifiques dirigés contre fap et dr5, anticorps spécifiques dirigés contre dr5 et leurs procédés d'utilisation | |
| MA39248B1 (fr) | Anticorps anti-jagged1 et procédés d'utilisation correspondants | |
| MA35898B1 (fr) | Anticorps anti-lrp5 et leurs procédés d'utilisation | |
| EA201890747A1 (ru) | Способы лечения воспалительных заболеваний | |
| MX374785B (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
| MA35712B1 (fr) | Anticorps anti-htra1 et leurs procédés d'utilisation | |
| MA39096B1 (fr) | Anticorps spécifiques à fcrn |